Study Stopped
Funding extension not granted
DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (In Vivo Phase)
DOLPHIN-VIVO
Diagnosis Of Lymphoma In Vivo Using Vibrational Spectroscopy (In Vivo Phase)
3 other identifiers
interventional
14
1 country
1
Brief Summary
Lymphoma diagnosis often involves removal and biopsy of one or more lymph nodes. Many (around half) of these diagnostic procedures show that no cancer is present, hence unnecessary removal results in numerous side effects and complications. The procedure is also highly invasive. The investigators have already shown that it is possible to tell the difference between healthy and diseased tissue in the laboratory by looking at the light emitted by tissue when a low power laser is shone on to it. The investigators intend to use this technique, known as "Raman Spectroscopy" (RS) to tell if tissue in the node is cancerous or healthy. By combining RS with a fine needle, the technique can target tissues below the skin with minimal invasion. Our needle will provide the clinician with instant diagnosis without the delay and cost of a laboratory analysis by pathologists. The investigators have designed a probe that slides through a fine needle, guided by ultrasound, to the lymph node. The space between the two needles provides space for cell aspirate. The investigators propose to measure spectra from excess lymph node biopsy samples taken during standard routine diagnostic biopsy. The investigators are also interested to see if they can successfully extract a fine needle aspiration (FNA) biopsy sample using the device, as well as record a RS measurement. If successful this would ease clinical adoption as the study could run in parallel with existing standard routine clinical practice, using just one device. This study will evaluate the new device on half a lymph node that will be excised and snap-frozen during a routine surgical biopsy, to gather data for submission of approvals for an in-vivo study to follow.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable lymphoma
Started Sep 2024
Shorter than P25 for not_applicable lymphoma
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 20, 2021
CompletedFirst Posted
Study publicly available on registry
August 18, 2021
CompletedStudy Start
First participant enrolled
September 2, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 26, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 17, 2025
CompletedJune 26, 2025
June 1, 2025
6 months
May 20, 2021
June 20, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Safety of in vivo measurement of lymph nodes using Raman spectroscopy to acquire diagnostic quality spectra
Testing of the device for clinical application during surgery to demonstrate its use is safe and that is able to acquire diagnostic-quality spectra in less than 5 seconds from lymph nodes.
3 years
Secondary Outcomes (1)
Safe in vivo measurement of lymph nodes using Raman spectroscopy to acquire diagnostic quality spectra
3 years
Study Arms (5)
non-hodgkin lymphoma
EXPERIMENTALpatients diagnosed with non-hodgkin lymphoma
hodgkin lymphoma
EXPERIMENTALpatients diagnosed with hodgkin lymphoma
squamous cell carcinoma
EXPERIMENTALpatients diagnosed with squamous cell carcinoma
reactive
EXPERIMENTALpatients diagnosed with a reactive (non-cancerous) lymph node
other
EXPERIMENTALnone of the above. Other cancer and non-cancer conditions
Interventions
measurement of the tissue with spectroscopy
a fine needle aspiration (FNA) biopsy will be taken
Histopathology and cytology will be performed on the samples
Eligibility Criteria
You may qualify if:
- Patients undergoing biopsy or excision of more than one lymph node as part of their routine clinical care within Gloucestershire Hospitals NHS Foundation Trust.
- Patients undergoing lymphadenectomy as part of routine treatment
You may not qualify if:
- Patients requiring biopsy of only one lymph node
- Patients unable to consent to the study due to communication difficulties
- Patients unable to consent to the study due to lack of capacity
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Exeterlead
- Gloucestershire Hospitals NHS Foundation Trustcollaborator
- University of Bristolcollaborator
Study Sites (1)
Gloucestershire Hospitals NHS Foundation Trust
Gloucester, Gloucestershire, GL1 3NN, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nick Stone
University of Exeter
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DEVICE FEASIBILITY
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 20, 2021
First Posted
August 18, 2021
Study Start
September 2, 2024
Primary Completion
February 26, 2025
Study Completion
June 17, 2025
Last Updated
June 26, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share
Unique study number and MRN (medical records number) (hospital number)